NYSE:MDT

Medtronic Stock Forecast, Price & News

$126.13
+0.22 (+0.17 %)
(As of 04/19/2021 12:00 AM ET)
Add
Compare
Today's Range
$125.10
Now: $126.13
$126.29
50-Day Range
$115.03
MA: $118.75
$125.85
52-Week Range
$87.68
Now: $126.13
$126.83
Volume3.88 million shs
Average Volume4.70 million shs
Market Capitalization$170.03 billion
P/E Ratio48.14
Dividend Yield1.84%
Beta0.7
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiac and Vascular Group, Minimally Invasive Therapies Group, Restorative Therapies Group, and Diabetes Group. The Cardiac and Vascular Group segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Minimally Invasive Therapies Group segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, hernia mechanical devices, mesh implants, and gynecology products; electrosurgical hardware and instruments, and mesh fixation devices; and gastrointestinal, inhalation therapy, and renal care solutions. The Restorative Therapies Group segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; colorectal surgeons; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The Diabetes Group segment offers insulin pumps and consumables, and continuous glucose monitoring systems. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Medtronic logo

Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryHealth Care Equipment
SectorMedical
CUSIP58505510
Phone353-1438-1700
Employees90,000
Year Founded1949

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$28.91 billion
Cash Flow$7.03 per share
Book Value$37.96 per share

Profitability

Net Income$4.79 billion

Miscellaneous

Outstanding Shares1,348,073,000
Market Cap$170.03 billion
Next Earnings Date5/20/2021 (Estimated)
OptionableOptionable

Headlines

The Top 3 Stocks to Buy in April (MDT)
March 30, 2021 |  marketbeat.com
Medtronic Is Healing Hearts and Padding Portfolios
April 15, 2021 |  finance.yahoo.com
Medtronic (NYSE:MDT) Hits New 52-Week High at $122.13
April 12, 2021 |  americanbankingnews.com
See More Headlines

MarketRank

Overall MarketRank

2.69 out of 5 stars

Medical Sector

4th out of 2,024 stocks

Electromedical Equipment Industry

1st out of 61 stocks

Analyst Opinion: 2.5Community Rank: 3.3Dividend Strength: 4.2Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -
$126.13
+0.22 (+0.17 %)
(As of 04/19/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MDT News and Ratings via Email

Sign-up to receive the latest news and ratings for MDT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Medtronic (NYSE:MDT) Frequently Asked Questions

Is Medtronic a buy right now?

23 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Medtronic in the last year. There are currently 3 hold ratings, 19 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Medtronic stock.
View analyst ratings for Medtronic
or view top-rated stocks.

What stocks does MarketBeat like better than Medtronic?

Wall Street analysts have given Medtronic a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Medtronic wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Medtronic's next earnings date?

Medtronic is scheduled to release its next quarterly earnings announcement on Thursday, May 20th 2021.
View our earnings forecast for Medtronic
.

How were Medtronic's earnings last quarter?

Medtronic plc (NYSE:MDT) released its earnings results on Tuesday, February, 23rd. The medical technology company reported $1.29 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $1.15 by $0.14. The medical technology company had revenue of $7.78 billion for the quarter, compared to analyst estimates of $7.77 billion. Medtronic had a trailing twelve-month return on equity of 9.71% and a net margin of 12.69%. Medtronic's revenue was up .8% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.44 EPS.
View Medtronic's earnings history
.

How has Medtronic's stock been impacted by Coronavirus (COVID-19)?

Medtronic's stock was trading at $92.44 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, MDT shares have increased by 36.4% and is now trading at $126.13.
View which stocks have been most impacted by COVID-19
.

How often does Medtronic pay dividends? What is the dividend yield for Medtronic?

Medtronic declared a quarterly dividend on Monday, March 8th. Stockholders of record on Friday, March 26th will be given a dividend of $0.58 per share on Friday, April 16th. This represents a $2.32 annualized dividend and a dividend yield of 1.84%. The ex-dividend date is Thursday, March 25th.
View Medtronic's dividend history
.

Is Medtronic a good dividend stock?

Medtronic pays an annual dividend of $2.32 per share and currently has a dividend yield of 1.84%. Medtronic has been increasing its dividend for 44 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio of Medtronic is 50.54%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Medtronic will have a dividend payout ratio of 39.86% next year. This indicates that Medtronic will be able to sustain or increase its dividend.
View Medtronic's dividend history.

What price target have analysts set for MDT?

23 Wall Street analysts have issued 1-year target prices for Medtronic's shares. Their forecasts range from $92.00 to $153.00. On average, they anticipate Medtronic's stock price to reach $125.33 in the next twelve months. This suggests that the stock has a possible downside of 0.6%.
View analysts' price targets for Medtronic
or view top-rated stocks among Wall Street analysts.

Who are Medtronic's key executives?

Medtronic's management team includes the following people:
  • Mr. Geoffrey Straub Martha, CEO & Chairman (Age 51, Pay $1.68M)
  • Ms. Karen L. Parkhill, Exec. VP & CFO (Age 56, Pay $1.81M)
  • Mr. Bradley E. Lerman, Sr. VP, Gen. Counsel & Corp. Sec. (Age 65, Pay $1.74M)
  • Mr. Mark Ploof, Sr. VP of Global Operations and Bus. Services
  • Dr. Richard E. Kuntz, Sr. VP & Chief Medical and Scientific Officer (Age 64)
  • Mr. Sean Lennon, Chief Information Officer
  • Mr. Ryan Weispfenning, VP of Investor Relations
  • Ms. Marguerite Copel, PR & Interim Chief Communications Officer
  • Ms. Carol A. Surface, Sr. VP & Chief HR Officer (Age 55)
  • Mr. Sean M. Salmon, EVP, Pres of Diabetes Operating Unit & EVP & Pres of Cardiovascular Portfolio (Age 55)

What is Omar S. Ishrak's approval rating as Medtronic's CEO?

1,925 employees have rated Medtronic CEO Omar S. Ishrak on Glassdoor.com. Omar S. Ishrak has an approval rating of 92% among Medtronic's employees. This puts Omar S. Ishrak in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Medtronic's key competitors?

What other stocks do shareholders of Medtronic own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Medtronic investors own include Johnson & Johnson (JNJ), AT&T (T), NVIDIA (NVDA), AbbVie (ABBV), The Walt Disney (DIS), Cisco Systems (CSCO), Intel (INTC), CVS Health (CVS), The Home Depot (HD) and Walmart (WMT).

What is Medtronic's stock symbol?

Medtronic trades on the New York Stock Exchange (NYSE) under the ticker symbol "MDT."

Who are Medtronic's major shareholders?

Medtronic's stock is owned by many different institutional and retail investors. Top institutional shareholders include Fort Pitt Capital Group LLC (0.04%), Saratoga Research & Investment Management (0.04%), Retirement Systems of Alabama (0.04%), Gateway Investment Advisers LLC (0.04%), Roffman Miller Associates Inc. PA (0.03%) and Calamos Advisors LLC (0.03%). Company insiders that own Medtronic stock include Bradley E Lerman, Carol A Surface, Geoffrey Martha, Hoedt Rob Ten, Hooman Hakami, Karen L Parkhill, Michael J Coyle, Omar Ishrak, Richard H Anderson, Richard Kuntz and Robert John White.
View institutional ownership trends for Medtronic
.

Which institutional investors are selling Medtronic stock?

MDT stock was sold by a variety of institutional investors in the last quarter, including FDx Advisors Inc., Gateway Investment Advisers LLC, Retirement Systems of Alabama, Calamos Wealth Management LLC, Hexavest Inc., Hodges Capital Management Inc., Clear Street Markets LLC, and State of Alaska Department of Revenue. Company insiders that have sold Medtronic company stock in the last year include Bradley E Lerman, Carol A Surface, Hoedt Rob Ten, Karen L Parkhill, Omar Ishrak, and Robert John White.
View insider buying and selling activity for Medtronic
or view top insider-selling stocks.

Which institutional investors are buying Medtronic stock?

MDT stock was bought by a variety of institutional investors in the last quarter, including Roffman Miller Associates Inc. PA, Polaris Wealth Advisory Group LLC, Systematic Alpha Investments LLC, Chemung Canal Trust Co., Landsberg Bennett & Dubbaneh LLC, FDx Advisors Inc., Edge Wealth Management LLC, and Hall Laurie J Trustee. Company insiders that have bought Medtronic stock in the last two years include Omar Ishrak, and Richard H Anderson.
View insider buying and selling activity for Medtronic
or or view top insider-buying stocks.

How do I buy shares of Medtronic?

Shares of MDT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Medtronic's stock price today?

One share of MDT stock can currently be purchased for approximately $126.13.

How much money does Medtronic make?

Medtronic has a market capitalization of $170.03 billion and generates $28.91 billion in revenue each year. The medical technology company earns $4.79 billion in net income (profit) each year or $4.59 on an earnings per share basis.

How many employees does Medtronic have?

Medtronic employs 90,000 workers across the globe.

When was Medtronic founded?

Medtronic was founded in 1949.

What is Medtronic's official website?

The official website for Medtronic is www.medtronic.com.

Where are Medtronic's headquarters?

Medtronic is headquartered at 20 ON HATCH LOWER HATCH STREET, DUBLIN L2, D02.

How can I contact Medtronic?

Medtronic's mailing address is 20 ON HATCH LOWER HATCH STREET, DUBLIN L2, D02. The medical technology company can be reached via phone at 353-1438-1700 or via email at [email protected]


This page was last updated on 4/19/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.